SVV-001
AXP000122.1 · Oncolytic virus
- Platform
- Seneca Valley virus (wild-type isolate)
- Originator
- Neotropix
- Sponsor
- Neotropix
Names
| Name | Type | Source |
|---|---|---|
| SVV-001 | preferred name, code | curator, ncit |
| NTX-010 | code | ncit |
| Seneca Valley Virus-001 | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Picornaviridae
- Virus
- Senecavirus A (NCBI Taxonomy 390157)
- Strain
- SVV-001 (wild-type isolate)
- Replication
- replicating
- Modifications
- none (wild-type isolate)
- Route
- intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C62524
Approvals
No regulatory approval recorded.
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06889493 | SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) | Recruiting | Phase 1 | 2025-05-19 | 2030-06-01 | 36 | Neuroendocrine Carcinoma; Neuroendocrine Tumors |
| NCT01017601 | Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer | Terminated | Phase 2 | 2010-01 | 2013-01 | 59 | Lung Cancer |
| NCT01048892 | Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features | Completed | Phase 1 | 2009-09 | 2013-06 | 22 | Adrenocortical Carcinoma; Gastrointestinal Carcinoid Tumor; Kidney Cancer; Neuroblastoma; Retinoblastoma; Sarcoma |
| NCT00314925 | Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | Unknown | Phase 1 | 2006-04 | 2008-12 | 60 | Carcinoid; Neuroendocrine |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 31605793 | A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020 | cited by trial NCT01017601 |
| PMID 25307519 | Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. | Pediatric blood & cancer | 2015 | name in title: NTX-010 |
| PMID 21304001 | Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2011 | name in title: SVV-001 |
| PMID 18391430 | Crystallization and preliminary X-ray diffraction studies of Seneca Valley virus-001, a new member of the Picornaviridae family. | Acta crystallographica. Section F, Structural biology and crystallization communications | 2008 | cited by trial NCT00314925 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 37415222 | Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models. | Journal of translational medicine | 2023 | name in title: SVV-001 |
| PMID 37749907 | Oncolytic virotherapies for pediatric tumors. | Expert opinion on biological therapy | 2023 | name in abstract: SVV-001 |
| PMID 36084546 | Characterisation of a Seneca Valley virus thermostable mutant. | Virology | 2022 | name in abstract: SVV-001 |
| PMID 36090051 | Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics. | Frontiers in molecular biosciences | 2022 | name in abstract: SVV-001 |
| PMID 36467495 | Progress of oncolytic virotherapy for neuroblastoma. | Frontiers in pediatrics | 2022 | name in abstract: NTX-010 |
| PMID 34332591 | Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis. | Virology journal | 2021 | name in abstract: NTX-010 |
| PMID 30029014 | Pathogenicity and cross-reactive immune responses of a historical and a contemporary Senecavirus A strains in pigs. | Virology | 2018 | name in abstract: SVV-001 |
| PMID 27371541 | Senecavirus A. | Veterinary pathology | 2017 | name in abstract: Seneca Valley Virus-001 |
| PMID 28475630 | Genome wide analysis of the evolution of Senecavirus A from swine clinical material and assembly yard environmental samples. | PloS one | 2017 | name in abstract: SVV-001 |
| PMID 27660749 | Oncolytic Seneca Valley Virus: past perspectives and future directions. | Oncolytic virotherapy | 2016 | name in abstract: SVV-001 |
| PMID 26069962 | Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy. | PloS one | 2015 | name in abstract: SVV-001 |
| PMID 23658322 | Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma. | Neuro-oncology | 2013 | name in title: SVV-001 |
| PMID 23739064 | Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. | Journal of the National Cancer Institute | 2013 | name in abstract: SVV-001 |
| PMID 22971818 | Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001. | The Journal of general virology | 2012 | name in title: SVV-001 |
| PMID 21075780 | A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. | Neuro-oncology | 2011 | name in title: SVV-001 |
| PMID 20582972 | Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. | Pediatric blood & cancer | 2010 | name in title: NTX-010 |
| PMID 18420805 | Complete genome sequence analysis of Seneca Valley virus-001, a novel oncolytic picornavirus. | The Journal of general virology | 2008 | name in title: Seneca Valley Virus-001 |
| PMID 18940610 | Structure of Seneca Valley Virus-001: an oncolytic picornavirus representing a new genus. | Structure (London, England : 1993) | 2008 | name in title: Seneca Valley Virus-001 |
| PMID 17971529 | Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. | Journal of the National Cancer Institute | 2007 | name in abstract: Seneca Valley Virus-001 |
| PMID 18006805 | Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus. | Cancer research | 2007 | name in abstract: SVV-001 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| M01RR000188 | ADVL0911 A PHASE 1 DOSE ESCALATION STUDY OF SENECA | BAYLOR COLLEGE OF MEDICINE | THOMPSON, PATRICK | 2011–2011 | name in abstract: SVV-001 |
Notes
Naturally occurring picornavirus with tropism for neuroendocrine tumours; development code NTX-010. Trials in small cell lung cancer and in paediatric neuroendocrine tumours. Discontinued; Neotropix no longer active.
How to cite
SVV-001 (AXP000122.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000122.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.